Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

NCT01305148 is registered in ClinicalTrials.gov with Iverson Genetic Diagnostics, Inc. as lead sponsor.

NCT NCT01305148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01305148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Lead sponsor
Iverson Genetic Diagnostics, Inc.
Phase
Not applicable
Overall status
Suspended
Start date
August 31, 2011
Completion date
December 31, 2015
Enrollment
3,800 (estimated)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

anti-coagulation therapy, atrial fibrillation, dvt, joint surgery multiple, prosthetic replacement of mitral valve, pulmonary embolism